ABSTRACT
of modern broad-spectrum antibiotics, mortality associated with SBP has diminished and is often reported as 20-40%. [4] [5] [6] [7] Clinical outcomes for some SBP patient populations remain poor despite increases in therapeutic options and availability of more effective antibiotics. 4, 8, 9 Unexplained fever, hypothermia, hypotension, encephalopathy, abdominal pain or unexplained clinical deterioration in cirrhotic patients are considered indications for diagnostic paracentesis. 3, 8, 10 Paracentesis has been associated with a short-term survival advantage 11 and should be performed before administration of antimicrobial therapy to assess for SBP. 3, 8, 10 Paracentesis reveals turbid ascitic fluid, an increased leukocyte count, with a predominance of polymorphonuclear leukocyte (PMN) cells. In the majority of cases, cultures of ascites fluid demonstrate a single enteric pathogen. 12 Although examination of serial ascitic fluid cell counts can demonstrate response to antibiotic therapy, guidelines appear to differ in their recommendations for repeat paracentesis at 48 hours. 3, 8, 10 A decrease in the ascites PMN cell count of less than 25% of the pre-treatment value at 48 hours is generally regarded as an indicator of antibiotic treatment failure. 8, 10 Some authors have challenged this percentage since an increased mortality and SBP relapse has been associated with unresponsiveness to therapy (defined as > 250 ascitic PMNs/mm 3 at 48 hours) despite significant relative declines in ascitic PMN cells. 5, [13] [14] [15] [16] We recently examined the prognostic significance of the Model of End-stage Liver Disease (MELD) scores in a Nepali SBP cohort. 17 That study demonstrated that deceased patients had a 1.7-fold greater ascites PMN count upon admission than survivors (2301 vs. 1365 cells/mm 3 ; p < 0.05). The current study assessed cirrhotic patients diagnosed with SBP with serial paracenteses to examine whether differences in serial ascitic fluid was associated with adverse outcomes during hospital admission. The specific objectives were to determine if there were: 1) relevant clinical or laboratory parameters obtained at admission that were associated with increased mortality; 2) significant differences in absolute ascites PMN counts and relative declines in response to therapy between survivor and deceased patients; and 3) if significant PMN thresholds could serve as prognostic indicators to identify and more aggressively manage the high risk cohort.
MATERIALS AND METHODS
Study design, clinical protocol, and data collection Process review revealed that a large number of the paracenteses performed in the non-survivor group were inconsistent with the timing stipulated by the study protocol.
Exclusion of this non-survivor data resulted in a smaller sample size, potentially compromising the power and external validity of the statistical analysis. Some would criticize excluding a large proportion of the data from the deceased group even if there were technical irregularities in the protocol's execution.
To address this concern, data were also analyzed using the original cohort of 33 deceased individuals.
Ethical consideration
The study protocol was approved by the institutional review board committee. All patients gave written informed consent to participate. Receiver operating characteristic (ROC) curves were constructed to determine the diagnostic performance of ascitic leukocytes at the three independent collection times.
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RESULTS
A total of 51 patients of the original 73 subjects diagnosed with SBP completed all the necessary laboratory investigations for inclusion in this analysis. The mean (± SD) age of patients in this study was 54.1 (± 10.8) years ranging from 28 to 74 years old, with 69% of patients greater than 50 years of age. The underlying pathology of cirrhosis in our study population was primarily due to alcohol (84%), with 12% of cryptogenic etiology and 4% attributed to hepatitis B. The overall mortality rate in this study was 21.6%.
Demographic data, clinical findings, and laboratory values for the deceased and survivors are presented in Table 1 . Using ANOVA with repeated measures, effects between the two groups and across time periods were significant (p < 0.001) before and after logarithmic transformation of the serial PMN counts. Additionally, progressive trends between the two groups were found to differ significantly (see Figure  1) , reflecting dissimilarities in their response over time (p = 0.006). Thus, although the non-survivors displayed greater initial ascitic PMN counts with greater absolute decreases in ascites leukocytes, there was a diminished relative decline over the 48-hour period as compared to the survivors. ROC curves were constructed at each of the three independent collection timesto determine whether ascitic PMN counts could serve as potential indicators of mortality. The area under the curves for the three time points varied from 0.95 to 0.99, indicating that all three analyses demonstrated robustness in their predictive value (p < 0.0001).
Figure 1:
Ascites polymorphonuclear leukocytes counts in deceased and survivor patients upon initial presentation, at 24 hours, and 48 hours after hospital admission.*
* Ascites polymorphonuclear leukocytes counts expressed as geometric means (± SE). Change of ascitic polymorphonuclear leukocytes over time differed significantly between deceased and survivor cohorts (p = 0.006, cohort by time interaction), within individual cohorts (p < 0.001), and at each time point (p < 0.001).
Ascitic PMN thresholds were established to maximize sensitivity in predicting mortality and are presented in Table 3 . Ascites PMN counts >1600 cells/mm 3 upon initial presentation, >860 cells/mm 3 at 24 hours, and >500 cells/mm 3 at 48 hours had a 100% sensitivity as predictors of mortality with specificities ranging from 82.5% to 97.5%. Positive predictive values at these three time points varied from 52.4% at 0 hours to 84.6% at 48 hours. Dotplots displaying the serial ascites leukocyte counts for the two groups with the prognostic thresholds for each time period are displayed in Figure 2 . Ascites PMNs counts at 0 and 24 hours were found to be independent determinants of in-hospital mortality. An increase of 500 PMNs in the ascites fluid was associated with 5-fold greater odds of mortality at admission and at 24 hours (Table 3) . Despite being the best predictor of mortality, the odds ratio at 48 hours could not be estimated because of the lack of overlap between survivors and non-survivors. To address the concern of the study's technical irregularities, the analysis was repeated using the original cohort of 33 deceased individuals (data not shown). There were minimal and alterations in albumin levels 5, 24 have been among the clinically significant risk indicators. Studies have demonstrated that persistent SBP and a lack of microbiological response is an independent risk factor for SBP-related mortality. 9, 13, 16, 18, 26 Healthcare-acquired infections, β-lactamase resistance or inadequate antibiotic coverage have also been associated with greater mortality in SBP patients. 4, 18, 26, [28] [29] [30] [31] [32] Prior recommendations have advocated a 25% decline in ascites PMN counts to reflect a favorable response to therapy. 8, 10 In the current study, average 48-hour declines in ascites PMNs were 68% in the deceased group, reinforcing the findings that relative declines may be less important than absolute counts in determining outcomes. Besides its small size, the current study has several potential limitations. Self-prescribing is a common practice in 
CONCLUSIONS
This study demonstrated that in-hospital mortality was associated with persistently elevated circulating and ascitic PMN counts in patients with cirrhosis and SBP. Ascitic PMNs in the non-survivors were not only elevated upon initial presentation but were also significantly elevated at 24 and 48 hours indicating a poor response to antimicrobial therapy.
The differences found between the two subpopulations were significant based on absolute leukocyte counts, relative differences and trends across time. Diagnostic thresholds were defined and determined to be robust and reliable in distinguishing those with a survival advantage upon admission, at 24 and 48 hours. Ascites PMN thresholds may be utilized to risk stratify patients and guide patient care, and is particularly suited for low-resourced settings. Additional prospective studies with larger sample sizes are needed to validate our findings of using ascites leukocytes as prognostic indicators and in ascertaining appropriate diagnostic thresholds.
